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Severe acute respiratory syndrome (SARS) is caused
by a novel coronavirus (SARS-CoV). In a longitudinal
cross-sectional study, we determined the prevalence of
virus in bodily excretions and time of seroconversion in dis-
charged patients with SARS. Conjunctival, throat, stool,
and urine specimens were collected weekly from 64
patients and tested for SARS-CoV RNA by real-time poly-
merase chain reaction; serum samples were collected
weekly and tested for SARS-CoV antibody with indirect
enzyme immunoassay and immunofluorescence assay. In
total, 126 conjunctival, 124 throat swab, 116 stool, and 124
urine specimens were analyzed. Five patients had positive
stool samples, collected in weeks 5–9. Two patients sero-
converted in weeks 7 and 8; the others were seropositive
at the first serum sample collection. In this study, 5 (7.8%)
of 64 patients continued to shed viral RNA in stool samples
only, for up to week 8 of illness. Most seroconversions
occurred by week 6 of illness.
S
evere acute respiratory syndrome (SARS), a newly-
defined condition identified in March 2003, is caused
by the novel SARS-associated coronavirus (SARS-CoV).
It is believed to have originated in Guangdong Province,
China, with subsequent spread to other cities and coun-
tries. By August 15, 2003, a total of 30 countries had
reported cases of SARS; 5 countries had local transmis-
sion. Approximately 8,500 cases were reported and at least
916 deaths (1). Singapore’s index case-patient was a 22-
year-old woman admitted to the hospital for atypical pneu-
monia on March 1, 2003; she had returned from a trip to
Hong Kong on February 25. An additional 237 cases were
identified and 33 deaths. The date of onset of illness of the
last patient was May 5, 2003.
The role of body fluids in transmission and the poten-
tial for transmission during convalescence remain unde-
fined. In Hong Kong, for example, faulty sewage works in
a residential block were deemed to be the cause of a major
outbreak in a residential estate (2). Excretion of the virus
RNA in bodily fluids has also been reported during the
convalescent phase (3), despite the patient’s apparent clin-
ical recovery. Detecting SARS-CoV in excreted bodily flu-
ids would thus have substantial implications on infection
control measures for recovered patients returning to the
community. 
The relationship of potential virus secretion to sero-
conversion is also undefined, as is the optimal time to test
for seroconversion. Seroconversion has been suggested to
occur at a mean of 20 days of illness (4). Recently avail-
able laboratory tests for detecting antibodies against
SARS-CoV provide a means to answer these clinical
questions.
A longitudinal cross-sectional study was designed to
study the prevalence of the virus and the duration of viral
shedding in bodily excretions (stool, urine, throat secre-
tions, and conjunctival tears) by using nucleic acid ampli-
fication tests on samples from patients who had recently
recovered from SARS. We also sought to determine the
factors for viral shedding and the time of seroconversion in
patients recovering from SARS. 
Methods
Patients
Patients for the study were recruited at the Tan Tock
Seng Hospital, Singapore, from April 30 to May 30, 2003.
The government designated this hospital for all SARS-
infected patients. A total of 233 of the 238 patients with
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Patients were identified from the existing patient reg-
istry maintained at the hospital. Selection criteria were a
diagnosis of SARS based on current World Health
Organization (WHO) recommendations (5) and being a
discharged patient. Patients were recruited into the study
anytime from the day of discharge up to 42 days after dis-
charge. Discharge criteria were based on existing WHO
recommendations (6). In our study, the endpoint of collec-
tion was arbitrarily set at 42 days after discharge. Given an
estimated 14- to 21-day hospital stay for each patient, our
study design would allow sampling up to days 56 to 63 of
illness. During the initial study design, one report (3)
showed viral RNA in stool samples from convalescent-
phase patients up to day 25 of illness. Collection of speci-
mens up to day 63 appeared sufficient. Adedicated team of
four doctors collected weekly specimens from the throat
and conjunctiva from each consenting patient. Fresh spec-
imens of midstream urine, stool, and blood were collected
concurrently in sterile specimen bottles. 
Sample Collection
A sterile swab was used to collect throat secretions
from the fornices and back of the throat. A spatula was
used to depress the tongue during the procedure. The swab
was then immediately placed in a bottle containing Hank’s
viral transport medium. By using a sterile swab, the con-
junctiva of one lower eyelid was swabbed with one brush.
The swab was then rotated 180°, and the conjunctiva of the
other lower eyelid was then swabbed similarly. The swab
was immediately placed in a bottle containing Hank’s viral
transport medium. Midstream urine was collected in a ster-
ile urine container. Stool specimens were collected with a
spatula into a sterile stool container. We accepted urine and
stool specimens that were delivered within 12 hours of col-
lection. Nine milliliters of blood was collected in tubes
with gel serum separators and kept at 4°C. All specimens
upon receipt, except blood, were kept at –70°C until
processed. Weekly collections of all the specimens were
repeated until 42 days after discharge. Information on
demographics and clinical course was collected.
Laboratory Test Methods
Laboratory tests were performed at the Department of
Pathology, Singapore General Hospital. Reverse transcrip-
tion–polymerase chain reaction (RT-PCR) was performed
on conjunctival, throat, stool, and urine specimens with the
RealArt HPA-coronavirus RT-PCR kit (Artus Gmbh,
Hamburg, Germany) on the Roche Lightcycler (Roche
Diagnostics Corporation, Indianapolis, IN), a real-time
PCR instrument. This assay targeted the polymerase gene
of SARS-CoV. All positive results were verified, with two
other primer pairs also targeted at the polymerase gene of
SARS-CoV. The first were primers designed by the
Genome Institute of Singapore (7), the second were Cor
1/2 primers from the Government Virus Unit, Hong Kong
(sense 5′ CAC CGT TTC TAC AGG TTA GCT AAC GA
3′, antisense 5′ AAA TGT TTA CGC AGG TAA GCG
TAA AA 3′) (8). Detection limit was set at 1 copy/µLo f
specimen. Serum specimens were tested for total virus-
specific antibodies with an indirect enzyme immunoassay
(EIA) with SARS-CoV lysate as the antigen (9). Positive
serum samples were retested for immunoglobulin (Ig) G
by immunofluorescence assay (IFA) with SARS-
CoV–infected Vero cells spotted onto microscope slides. 
Statistical Analysis
During recruitment, patients were selected on the basis
of the number of days after the patient was discharged
from the hospital. During analysis, this date was converted
to day of illness, and subsequently week of illness, by
determining the date of onset of illness. Onset of illness
was defined as the day of onset of fever. For example,
specimens collected from day 15 to 21 of illness were thus
grouped into week 3 of onset of illness. Statistical analyses
were performed with SPSS for Windows release 10.0.1
(SPSS, Inc., Chicago, IL). Categorical variables were ana-
lyzed with chi-square test. The student t test was used to
analyze continuous variables.
Results
Patients
A total of 170 patients met the selection criteria, 64
patients consented to the study, and 4 patients withdrew
after the first collection. The mean age of consenting
patients was 35.2 years (range 17–63 years), and 25% were
men. The mean age of all SARS patients in Singapore was
35 years (range 1.3– 90 years), and 32.4% were male.
Patients for this study were recruited from week 3 to 9 of
their illness (median week 7) (Figure 1). Most patients
(89%) were recruited after week 4 of illness.
Ten participants had coexisting conditions (diabetes
mellitus, hypertension, asthma). Four had a history of pre-
vious intensive care admission. During their hospital stay,
six had history of steroid treatment, defined as prior use of
hydrocortisone, prednisolone, dexamethasone, or pulsed
methylprednisolone, regardless of dosage and frequency.
Ribavirin was used in the treatment of 32 patients (50%). 
Laboratory Investigations 
Since an interim analysis on 60 specimens indicated no
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made to stop all subsequent collections until after day 28
of discharge. Specimens already collected were processed. 
In total, 126 conjunctival specimens, 124 throat swab
specimens, 116 stool specimens, 124 urine specimens, and
123 blood specimens were available for analysis. An aver-
age of 9.6 specimens was taken per patient (range 4–19).
All patients had at least one specimen of each type taken.
RT-PCR
Most (76%) specimens collected for RT-PCR testing
were taken from week 6 to 8 of illness (mean 6.3 weeks,
standard deviation [SD] 1.47). All specimens from throat,
conjunctiva, and urine were negative for SARS-CoV by
RT-PCR. Six stool specimens from five patients were pos-
itive by the three RT-PCR assays (Figure 2).
Relevant clinical histories and laboratory data for these
patients are summarized in the Table. The five patients
with positive viral RNAin stool specimens had a mean age
of 31.6 years; two (40%) of the five patients required sup-
plemental oxygen. No patients were admitted to intensive
care. Mean peak lactate dehydrogenase (LDH) was
811 U/L. The 59 patients with stool samples negative for
SARS-CoV RNA had a mean age of 35.9 years, 33%
required supplemental oxygen, and 4 were previously
admitted to intensive care. Mean peak LDH for the
patients without RNA detected in stool samples was
764 U/L. Age, prior supplemental oxygen use, and peak
LDH were not statistically different in the two groups.
Patients 3 and 62 provided one sample each and with-
drew from the study immediately thereafter. Both were
positive for SARS-CoV by RT-PCR in week 5 of illness.
No subsequent specimens were available for analysis.
Three stool specimens were taken from patient 16 on
weeks 4–6 of illness. Only specimens taken in week 4
were positive. Patient 51 provided two stool specimens for
week 5 and 6; both were positive. The sample taken in
week 6 had fewer copies per reaction on RT-PCR com-
pared to that taken in week 5. A sample requested by her
physician, outside this study, was collected on week 10 of
illness and tested negative by RT-PCR. Patient 35 provid-
ed one sample, which was positive, at week 9 of illness. No
subsequent specimens were available. 
Of the five patients with positive SARS-CoV detected
by RT-PCR in the stool sample, one (patient 3) had a his-
tory of prior steroid treatment during SARS illness. As
mentioned earlier, this patient provided one sample before
withdrawing from the study. Five other patients received
steroid treatment during their hospitalization, but none had
SARS-CoV detected by RT-PCR. These patients were
recruited from week 5 to 7 of illness. 
Of the 32 patients who received ribavirin, two had sam-
ples positive for SARS-CoV RNA. In comparison, 3 of the
32 patients who did not receive ribavirin had SARS-CoV
detected by RT-PCR. This difference was not significant.
Diarrhea was reported in 19 (30%) of our study patients;
one had a sample positive for SARS-CoV RNA. The
remaining RNA-positive samples were from patients who
did not report any diarrhea symptoms during their hospital
stay. Ten of our participants had a history of chronic ill-
nesses. Three had asthma, five had hypertension, and one
had diabetes mellitus type 2. One additional patient had
diabetes mellitus type 2 and hypertension. Samples were
collected from these patients on weeks 5 to 9 of illness
(mean 6.3 weeks [SD 1.22]). None of these patients had
SARS-CoV viral RNA detected in our study. 
Serologic Testing
A total of 123 specimens from 64 patients were avail-
able for analysis. All specimens were positive by EIA, with
the exception of two specimens taken at week 7 and 6 from
patients 4 and 5, respectively. All positive results were cor-
roborated with a positive IFA, except for a sample from
patient 38, which was negative by IFA on week 5 of ill-
ness. The next sample taken on week 6 was positive on
both EIA and IFA. The result of the first sample of blood
taken for serologic testing was plotted against the respec-
tive week of illness (Figure 3). For patients 5 and 4, whose
initial results were negative, serologic test results became
positive at the subsequent week of testing (weeks 7 and 8,
respectively)
Discussion 
SARS-CoV detected in mucosal secretions or excreta
will affect decisions about discharging patients. Detecting
SARS-CoV would have a greater importance if it was
detected in the respiratory tract (throat swabs) or tears
(conjunctival swabs). By testing samples from patients
who were discharged from the hospital, we accessed
patients deemed clinically fit to return to the community. A
positive RT-PCR result in these patients would be more
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Figure 1. Recruitment of patients by week of illness.important compared to results of those patients recovering
in the hospital. Weekly tests were conducted to assess this
risk by using molecular diagnostic methods. This is the
first longitudinal cross-sectional study of viral shedding in
convalescent-phase SARS patients. 
By performing weekly tests, the optimal time of sero-
conversion in recovering patients could be determined.
This information will assist clinicians in planning a rea-
sonable time for serologic testing in patients with suspect-
ed cases of SARS. 
In our study, viral nucleic acid for SARS-CoV was
detected only in the stool samples. This finding was infre-
quent; most patients (>95%) did not have positive samples
after week 5 of illness (Figure 2). One patient still had
detectable viral RNA at week 9 of illness. None of our
patients had viral nucleic acid for SARS-CoV detected in
respiratory, urine, or conjunctival samples.
Detection of viral nucleic acid for SARS-CoV in stool
samples of recovering patients has been reported. Samples
were positive up to day 25 in a study by Drosten et al. (3)
and at day 73 in a study by Leung et al. (10). The Drosten
et al. study involved two patients; both had viral RNA
detected during the convalescent phase on day 19 and 25
of illness. In the Leung et al. study, the authors examined
the gastrointestinal manifestations of the 138 patients with
SARS who were admitted to a local hospital. The overall
detection rate of SARS-CoV RNA in stool specimens was
16%. Whether these samples were taken during the acute
phase, convalescent phase, or both is unknown. The
authors observed that in one patient, viral RNAwas detect-
ed in a stool sample up to 73 days after symptom onset. No
other clinical information was available for this patient. 
In a later study, Chan et al. (11) reported that viral RNA
was detected in ≈5% of stool samples submitted after week
7 of illness. The last positive sample was detected at week
11 of illness; in that study, the respiratory samples (tra-
cheal aspirates, nasopharyngeal aspirates, throat swabs,
throat washings, nasal swabs, and pooled throat and nasal
swabs) were detected at week 8 of illness. All those who
shed virus for a prolonged period (arbitrarily defined as >6
weeks after onset of symptoms) had samples collected
while still critically ill. This study had a different cohort of
patients compared to ours. Our patients had been dis-
charged and had comparatively shorter and milder illness-
es. Determining whether positive carriage persisted in
these critically ill patients from the Chan et al. study after
discharg would be beneficial. 
SARS-CoV was not isolated in this study, so we were
unable to assess if those with positive stool samples were
infectious. However, in the Chan et al. study (11), 2 (1%)
of the 195 samples submitted for stool isolation were
1748 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 10, October 2004
RESEARCH
Figure 2. Results of severe acute respiratory syndrome–associat-
ed coronavirus polymerase chain reaction (PCR) on stool samples
plotted by week of illness. Samples were processed for reverse
transcription (RT)-PCR. Any result was deemed positive if it was
detected by both the RealArt HPA-coronavirus RT-PCR kit (Artus
Gmbh, Hamburg, Germany) and two other RT-PCR primers
designed by Genome Institute of Singapore and the Government
Virus Unit, Hong Kong.positive, only during week 1 of illness. In the study by
Leung et al. (10), virus was not isolated from stool sam-
ples. This finding was similar to our own experience in
Singapore. Our laboratory was the primary center for
SARS-CoV isolation during the epidemic, and we had not
been successful in isolating viruses from stool samples. A
stool sample positive for SARS-CoV, from convalescent-
phase SARS patients, would probably have a minimal
effect on the public. Secondary SARS cases from conva-
lescent-phase SARS patients discharged from the hospital
have not been reported. We, however, still recommend
caution, especially in pediatric patients and adults requir-
ing full nursing aid, since SARS-CoV can survive for at
least 2 to 4 days at room temperature (12). 
With a greater severity of illness, excretion of the virus
would likely be prolonged. We identified severity of illness
by a history of supplemental oxygen use, admission to
intensive care, or a high peak LDH. Peak LDH has been
identified along with advanced age as predictors of adverse
outcomes in Hong Kong (13,14). However, in our study
patients, age, supplemental oxygen use, and peak LDH
were not statistically different between those who had pos-
itive stool samples and those who had negative stool sam-
ples. Samples from all four patients with a previous history
of intensive care admission were negative for SARS-CoV
RNA by RT-PCR. This finding suggests that the duration
of viral RNA excretion in the convalescent phase may not
be solely determined by severity of illness. However, the
number of intensive care patients in the study was small.
Six patients (9.4%) in our study received steroid treat-
ment compared to 17.2% of the SARS cohort in Singapore.
Stool samples from one patient were positive for RNA.
Possible explanations for this finding include the small
numbers of those treated with steroids in our study and the
fact that all those who had stool samples negative for RNA
who were on steroids were recruited late in their illness
(weeks 5–7). 
SARS-CoV viral RNA was not detected in stool sam-
ples from the 10 patients with chronic illnesses. All those
who did have SARS-CoV viral RNA had no history of
chronic illnesses. Again, a possible explanation is the
recruitment of patients late in their illness. 
The use of ribavirin did not appear to reduce the detec-
tion rates of viral RNA in the stool sample. This finding
concurred with observations from in vitro studies (15) and
retrospective cohort studies (16), which suggested that rib-
avirin was not effective against SARS-CoV. In a separate
study, Leong et al. (17) showed that ribavirin did not con-
fer any survival benefit for patients with SARS. 
Active replication of SARS-CoV has been reported in
the small and large intestine (10). Diarrhea was not associ-
ated with a higher proportion of patients with SARS-
CoV–positive stool samples. The increased intestinal
motility caused by diarrhea might lessen the viral load in
the gastrointestinal tract in those patients with symptoms. 
In Hong Kong (4), IgG seroconversion was detected
from day 10 of illness (mean of 20 days). Ninety-three
percent of patients seroconverted by day 30 (week 5) of ill-
ness. As part of the protocol, all patients received steroids
(intravenous hydrocortisone, oral prednisolone, or pulse
methylprednisolone) on diagnosis of SARS. Steroids did
not appear to affect seroconversion rates. The Toronto
group (18) reported similar results. Seropositivity rate was
96.2% at 28 days of illness and beyond. 
All but two of our patients demonstrated positive EIA
results at the initial specimen collection. These results
were expected, since most patients were recruited after
week 4 of illness. At week 6 of illness, 27 (96%) of 28
patients had a positive serologic result. Patients 5 and 4
demonstrated seroconversion at week 7 and 8 of illness,
respectively. This finding is congruent with the Hong
Kong study; therefore, the diagnostic role of serologic test-
ing is limited in the acute phase of illness. 
Steroid use was infrequent (6 patients) in our study.
Patient 5 received intravenous hydrocortisone during her
hospital stay. The other five participants who received
steroids during their hospital stay had detectable antibod-
ies at the first specimen collection, performed at week 5
(four patients) and week 7 (one patient). Patient 4 sero-
converted at week 8, and she had no prior steroid use,
which suggests that the serologic response is not muted by
the use of steroids. The two patients who seroconverted
during these sequential weekly collections had ribavirin
and symptoms of diarrhea during their hospital stay.
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Figure 3. Cumulative results of first serologic testing of samples by
week of illness. Serologic testing was performed by indirect
enzyme immunoassay with severe acute respiratory
syndrome–associated coronavirus lysate as the antigen.Our study had limiting factors. The design of this study
was cross-sectional, which did not allow us to accurately
determine when seroconversion occurred or when viral
RNA ceased to be detectable. Most of our patients did not
have severe illness, and most intensive care patients
declined to participate. Returning to the hospital on a
weekly basis for specimen sampling was also difficult
because these patients had substantial sequelae from the
infection. Even when recruited, participants were already
in the later half of their convalescence. These patients have
had more severe illness and would have had a longer hos-
pital stay. At the time of discharge, they would have been
beyond week 4 of illness. Our study had few participants
in the early phase of recovery. The outbreak in Singapore
was already under control when the study commenced at
the end of April, which further limited the number of eli-
gible participants in the early convalescent phase.
Conclusion
Detection of SARS-CoV RNA is uncommon in recov-
ering patients discharged from the hospital. In this study,
RT-PCR determined that 5 (7.8%) of 64 patients continued
to shed viral RNA in stool samples only, up to week 8 of
illness. Most seroconversions (96%) occurred by week 6
of illness, although seroconversion may still occur at week
7 and 8 of illness. Excretion of viral RNA and seroconver-
sion did not appear to be related to age, underlying condi-
tions, diarrhea, prior steroid or ribavirin use, or severity of
illness. No secondary cases of infection occurred among
the convalescent-phase patients.
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